MEDENZYMEDESIGN

Enzyme Design of Medical Interest

Coordinatore	UNIVERSITAT DE GIRONA    more  Organization address address: PLACA SANT DOMENEC 9 EDIFICI LES ALIGUES city: GIRONA postcode: 17071 contact info Titolo: Dr. Nome: Montserrat Cognome: Estopà Email: send email Telefono: -972419711 Fax: -972418862
Nazionalità Coordinatore	Spain [ES]
Totale costo	223˙537 €
EC contributo	223˙537 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-IOF
Funding Scheme	MC-IOF
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-10-01   -   2013-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAT DE GIRONA  Organization address address: PLACA SANT DOMENEC 9 EDIFICI LES ALIGUES city: GIRONA postcode: 17071 contact info Titolo: Dr. Nome: Montserrat Cognome: Estopà Email: send email Telefono: -972419711 Fax: -972418862	ES (GIRONA)	coordinator	223˙537.90

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Enzymes are the most efficient, specific and selective catalysts known up to date. Despite the enzyme advantages, not all synthetic processes present a natural enzyme to catalyze and accelerate the reactions. Hence, the design of new stable enzymes for those processes where no biocatalyst is known represents a major challenge for protein engineering and a stringent test to understand how natural enzymes work. In addition to that, the ability of designing specific active enzymes is of great interest due to the potential applications in biotechnology, biomedicine and industrial processes. In this proposal, the design of three enzymes of biological/medical interest will be fulfilled. First, an enzyme to reverse the formation of Advanced Glycation End-Products (AGEs), mainly associated to diabetes-related disorders, but also to Alzheimer’s disease will be designed. Second, the design of an enzyme presenting Glucose-6-Phosphate Dehydrogenase (G6PD) activity will be pursued. The latter might avoid the oxidative stress induced by many drugs in G6PD-deficient persons. Finally, the third objective of this proposal is the design of an enzyme with superoxide dismutase activity to avoid the oxidative stress produced in most of neurodegenerative diseases (i.e. Alzheimer’s, Parkinson’s, Huntington’s disorders). All designs will be performed following the research methodology developed by the Prof. Houk group which was already successfully applied for the design of active Kemp elimination and retro-aldolase enzymes. However, new QM/MM-MD strategies and DFT functionals developed at the return host organization (IQC) will be introduced to improve some parts of the design process. The fellow researcher will have the chance to work on this pioneer project in a world leading research group and to transfer this knowledge to one of the best EU research institutes.'

Introduzione (Teaser)

Enzymes are efficient catalysts with high specificity and selectivity that are biodegradable and non-toxic and have enormous potential in sustainable industrial-scale production of many drugs. Limitations are the lack of stable natural enzymes and issues with scalability and cost.